One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

The genetic testing results also inform patients’ family members about their cancer risks so they can be proactive in screening and prevention. For now, GENETECA™ is only available to people with ...

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...

"Not only does this provide a potential treatment option for eligible men with earlier stage disease, but it is the first and only PARP inhibitor that has demonstrated superior rPFS compared to ...

“There was a real reason to think that dialling out PARP2 might make PARP inhibitors better tolerated ... better tolerated as a long-term treatment, which we know is going to be important.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments ...